Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Gregory Berk
AddedJul 2, 2026
UpdatedJul 10, 2026
Gregory Berk

Gregory Berk

Chief Medical Officer, Allorion Therapeutics

Website

Gregory Berk's Career

Allorion Therapeutics
Allorion Therapeutics

Natick, MA, US

Chief Medical Officer

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Gregory Berk's Career

Allorion Therapeutics
Allorion Therapeutics
Series B$90M272020Natick, MA, US
Chief Medical Officer

Recent news

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective InhibitorAvenzo Therapeutics · 2025
Avenzo Therapeutics announces global license of AVZO-021 (ARTS-021), a potentially best-in-class clinical stage CDK2 inhibitor from Allorion TherapeuticsPR Newswire · 2024
Allorion Therapeutics announces exclusive option and global license agreement for novel preclinical-stage EGFR L858R allosteric inhibitor program with AstraZenecaPR Newswire · 2024

Leadership at Allorion Therapeutics

Qiang DingQiang DingCEO
Yaoyu ChenYaoyu ChenCo-Founder
Fang LiFang LiCo-Founder

Similar to Allorion Therapeutics

Orionis BiosciencesOrionis BiosciencesWaltham, MA, USBiotech, Drug Discoveryest. 2015Orionis BiosciencesWaltham, MA, US · est. 2015

Orionis Biosciences: Pioneering disruptive tech for innovative drug discovery and disease treatment.

Series C · $79.5M48
Azora TherapeuticsAzora TherapeuticsLos Angeles, CA, USTherapeuticsest. 2017Azora TherapeuticsLos Angeles, CA, US · est. 2017

Azora Therapeutics develops innovative therapies for serious inflammatory diseases using novel small molecules.

Pre-Seed · $8.3M2
Allyx TherapeuticsAllyx TherapeuticsNew Haven, CT, USTherapeuticsest. 2018Allyx TherapeuticsNew Haven, CT, US · est. 2018

Allyx Therapeutics: Clinical-stage biotech firm developing therapies to combat Alzheimer's disease.

Seed · $10.1M4
Allterum TherapeuticsAllterum TherapeuticsHouston, TX, USCancer Treatment, Immunotherapyest. 2018Allterum TherapeuticsHouston, TX, US · est. 2018

Biopharmaceutical firm, Allterum Therapeutics, innovates immunotherapies for various IL-7R expressing cancers.

Seed · $4.7M6

People Similar to Gregory Berk

Kenneth GreggKenneth GreggFounder · Orion180Timo LappalainenTimo LappalainenBoard Member · OrionTravis BooneTravis BooneCEO · Orion Group Holdings